Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS WELCOMES STEPHEN GLOVER TO ITS BOARD OF DIRECTORS

Preveceutical Medical Inc.'s wholly owned subsidiary, BioGene Therapeutics Inc., has appointed Stephen Glover as an independent director, effective on Nov. 30, 2024.

Stephen Van Deventer, chief executive officer of BioGene, commented: "We are honoured to welcome Stephen Glover to our board of directors. Stephen's proven leadership in biopharma, combined with his expertise in corporate strategy, commercialization and financial management, makes him an invaluable addition to our team. His track record of building and transforming organizations aligns seamlessly with BioGene's mission to advance groundbreaking therapies."

About Mr. Glover

Mr. Glover is an accomplished executive with over three decades of leadership experience in the biopharma industry. Currently, he serves as chairman and chief executive officer of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company focused on innovative treatments for inflammatory and kidney diseases. Mr. Glover has successfully led multiple organizations, securing over $500-million in capital and creating more than $7-billion in shareholder value.

Previously, Mr. Glover was chairman of Ambrx, overseeing its $2-billion acquisition by Johnson & Johnson. He also co-founded Coherus BioSciences, where he developed strategic partnerships valued at over $300-million. Mr. Glover's operational expertise spans commercialization, integrated product development and governance, having overseen the launch of over 25 products in multiple therapeutic areas.

In addition to his extensive executive experience, Mr. Glover serves on the board of publicly traded companies, including as chairman of PDS Biotechnology, a Nasdaq company, and the University of Miami Coulter Foundation, bringing insights into audit, compensation and governance practices.

Mr. Glover remarked on his appointment: "I am excited to join BioGene's board of directors and support the company's vision of delivering transformative therapies. BioGene's innovative approach to addressing unmet medical needs resonates deeply with my own professional passion, and I look forward to contributing to its success."

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity, the Sol-gel program, Nature Identical peptides for treatment of various ailments, non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene Therapeutics is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D (research and development) tax cashback incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.